Adaptimmune Competitors, Revenue, Alternatives and Pricing
Overview
Estimated Revenue & Financials
- Adaptimmune's estimated annual revenue is currently $64.3M per year.
- Adaptimmune received $Undisclosed in venture funding in March 2017.
- Adaptimmune's estimated revenue per employee is $155,000
Employee Data
- Adaptimmune has 415 Employees.
- Adaptimmune grew their employee count by 0% last year.
- Adaptimmune currently has 1 job openings.
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Online Review | Pricing |
---|---|---|---|---|---|---|
Advertise Here | ||||||
#1 | $64.3M | 415 | 0% | N/A | - | N/A |
What Is Adaptimmune?
Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page.
keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power415
Number of Employees
$64.3M
Revenue (est)
1
Current Jobs
0%
Employee Growth %
N/A
Total Funding
N/A
Valuation
N/A
Accelerator
B2B
Type
Adaptimmune News
Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation ...
Adaptimmune formed a preclinical research pact. InDex Pharmaceuticals presented phase 2b ulcerative colitis data. And more. — Nick Taylor
Adaptimmune Therapeutics (NASDAQ:ADAP) announced on Tuesday (August 27) it will be partnering with Japan-based Noile-Immune ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding | Online Review | Pricing |
---|---|---|---|---|---|---|
#1 | $76.1M | 423 | N/A | N/A | - | N/A |
#2 | $45M | 441 | 8% | N/A | - | N/A |
#3 | $94.1M | 466 | N/A | N/A | - | N/A |
#4 | N/A | 674 | N/A | N/A | 5/5 | N/A |
#5 | $140M | 859 | 5% | N/A | - | N/A |
Adaptimmune Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2014-09-26 | $104.0M | Undsiclosed | Multiple | Article |
2017-03-23 | $Undisclosed | Undisclosed | Citigroup | Article |
Adaptimmune Executive Hires
Date | Name | Title | Reference |
---|---|---|---|
2013-12-02 | Jonathan Knowles | Executive Chairman | Article |
2017-10-25 | Sébastien Desprez | VP Communications and Investor Relations | Article |
2018-01-05 | Paul Stead | VP Business Development | Article |